期刊文献+

PAK6基因沉默对前列腺癌细胞放疗敏感性研究 被引量:2

Effects of PAK6-shRNA Silence on Radio Sensitivity of Prostate Cancer
下载PDF
导出
摘要 为探讨p21活化激酶6基因沉默对雄激素依赖性前列腺癌细胞株LNCa P细胞放疗敏感性的影响。采用利用蛋白质免疫印迹技术检测筛选出的靶向PAK6的sh RNA对LNCa P细胞中PAK6蛋白表达抑制情况。并以靶向PAK6的sh RNA转染LNCa P细胞,分别给予0、1、3、5Gy单次剂量放射治疗,观察放疗对PAK6基因沉默的前列腺癌细胞的抑制作用。用CCK-8法检测前列腺癌细胞的增殖活性;流式细胞仪测定其凋亡变化。结果显示,放疗能抑制前列腺癌细胞的增殖,增加其凋亡率;接受等剂量照射的PAK6基因沉默组前列腺癌细胞增殖减缓更明显,凋亡的肿瘤细胞显著增多。由此可知,PAK6基因沉默的前列腺癌细胞对放射治疗更敏感。 To study the effects of PAK6 silencing on human prostate cancer cell line LNCaP radio sensitivity.Methods: Western blotting was adopted to detect the expressions of PAK6 proteins in I,NCaP cells trausiected by PAK6-shRNA. LNCaP cells were transfected by PAK6-shRNA through the liposome and were locally irradiated with single dose of 0,1,3,5 Gy radiation.The prostate cancer cells inhibition by radiotherapy was observed.The proliferation and apoptosis of LNCaP cells were detected by CCK-8 and ilow cytometry respectively.Radiotherapy could inhibit the proliferation of LNCaP cells and induced apoptosis in LNCaP eells.h was apparently in PAK6 silencing group than in LNCaP group irradiated by the same dose. LNCaP silenced by PAK6-shRNA are more sensitive to radiotherapy.
出处 《石河子大学学报(自然科学版)》 CAS 2015年第6期732-735,共4页 Journal of Shihezi University(Natural Science)
基金 国家自然科学基金项目(81560129) 石河子大学基础研究项目(2012ZRKXYQ23)
关键词 前列腺癌 p21活化激酶6 放射治疗 基因沉默 LNCAP细胞 prostate cancer (PCa) p21 -activated kinase 6 (PAK6) radiotherapy gene silencing LNCaP cells
  • 相关文献

参考文献12

  • 1Schrantz N, Correia J S, Fowler B,et al.Mechanism ofp21-aet ivated Kinase 6-mediated inhibition nf AndrogenReeeptor Signaling[J]J Biol Chem, 2004,279(3) : 1922-1931.
  • 2王新敏,章乐,王勤章,丁国富.前列腺癌与前列腺增生组织中P21活化激酶6的表达及意义[J].中国老年学杂志,2011,31(16):3013-3015. 被引量:3
  • 3王新敏,王勤章,章乐,丁国富.雄激素受体与P21活化激酶6在前列腺癌组织中的表达及意义[J].石河子大学学报(自然科学版),2010,28(1):79-82. 被引量:3
  • 4Steinkamp M P, Mahony 0 A, Brogley M,et al.Treatmentdependent androgen receptor mutations in prostate cancerexploitmultiple mechanisms to evade therapy[J].Cancer Res,2009,69(10):4434-4442.
  • 5Brooke G N, Bevan C L.The role of androgen receptorm-utations in prostate cancer progression [J].CurrGenomics,2009,10(1):18-25.
  • 6Denayer S,Helsen C,Thorrez L,et al.The rules of DNArecognition by the androgen receptor [J].Mol Endocrinol,2010,24(5):898-913.
  • 7Ratna KVadlamudi and Rakesh Kumar.p21 -activated kinasesin human cancer[J].Cancer and Metastasis Reviews, 2003,22(4):385-393.
  • 8Ramneet K,Xia L,Ole G,et al.Activation of p21 -activatedKinase 6 by MAP Kinase Kinase 6 and p38 MAP Kinase[J].The journal of biological chemistry,2005,280(5):3323-3330.
  • 9Ui L X,Wang W Q,Ye L,et al.p21 - Activated kinase 3 isoverexpressed in thymic neuro endocrine tumors(carcinoicls)with ectopic ACTH syndrome and participates in cellmigration[J].Endocr T 2010,38(1) : 38-47.
  • 10Wen X,Li X,Liao B,et al .Knockdown of p21-activatedkinase 6 inhibits prostate cancer growth and enhances ch-emosensitivity to docetaxel[J].Urology, 2009,73(Q : 1407-1411.

二级参考文献22

  • 1Floey R, Hollywood D, Lawler M. Molecular pathology of prostate caner: the key to identifying new biomarkersof disease[J]. Endocrine-Related Cancer, 2004,11 : 477-483.
  • 2Denmeade S R, Isaacs J T. A history of prostate cancertreatment[J]. Nature Reviews Cancer, 2002,2 : 389-396.
  • 3Burd C J, Morey L M, Knudsen K E. Androgen receptor corepressors and prostate cancer[J]. Endocrine-Related Cancer, 2006,13 : 979-994.
  • 4Cotteret S,Jaffer Z M, Beeser A, et al. p21-activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD [J]. Mol Cell Biol, 2003,23(4):5526-5539.
  • 5Thorson P A. Minimal adenocareinoma in prostate needle[J]. Am J Clin Pathol,2000,114(6) :896-909.
  • 6Li T H,Zhao H J,Peng Y,et al. A promoting role of androgen receptor in androgen-sensitive and-insensitive prostate cancer cells[J]. Nucleic Acids Research, 2007,35 (8) : 2767-2776.
  • 7Jeffrey S. The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test[J]. Advances in Anatomic Pathology, 2007,14 (5): 353-355.
  • 8Andrew C,CharlesJ M D. Novel Concepts in Androgen Receptor Blockade[J]. Cancer Journal, 2008, 14 ( 1 ) : 11-14.
  • 9Heinlein C A, Chang C. Androgen receptor in prostate cancer[J].Endocr Rev, 2004,25 (2) : 276-308.
  • 10Amirghofran Z, Monabati A, Gholijani N. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer[J]. Pathol Oncol Res,2004,10(1) :37-41.

共引文献4

同被引文献32

  • 1林锦娜,刘强.2019年NCCN乳腺癌临床实践指南更新解读:乳腺癌局部治疗新进展[J].临床外科杂志,2020,0(1):27-30. 被引量:41
  • 2杨少东,曾春贤,张志尚,张进华,李小娟,廖星海,温志强,郑清友.PAK6在前列腺癌中的表达及临床意义[J].湖南师范大学学报(医学版),2020,17(3):40-43. 被引量:1
  • 3KANEKO H, FUKAO T, KASAHARA K, YAMADA T, KONDO N. Augmented cell death with Bloom syndrome helicase deficiency[J]. Mol Med Rep, 2011, 4: 607-609.
  • 4RAMACHANDRAN P V, IGNAEIMUTHU S. RNA interference——a silent but an efficient therapeutic tool[J]. Appl Biochem Biotechnol, 2013, 169: 1774-1789.
  • 5JIN X, SUN T, ZHAO C, ZHENG Y, ZHANG Y, CAI W, et al. Strand antagonism in RNAi: an explanation of differences in potency between intracellularly expressed siRNA and shRNA[J]. Nucleic Acids Res, 2012, 40: 1797-1806.
  • 6SELKIRK M E, HUANG S C, KNOX D P, BRITTON C. The development of RNA interference (RNAi) in gastrointestinal nematodes[J]. Parasitology, 2012, 139: 605-612.
  • 7PENG A, WANG L, FISHER L A. Greatwall and Polo-like kinase 1 coordinate to promote checkpoint recovery[J]. J Biol Chem, 2011, 286: 28996-29004.
  • 8GONDI C S, RAO J S. Concepts in vivo siRNA delivery for cancer therapy[J]. J Cell Physiol, 2009, 220: 285-291.
  • 9KIM D H, ROSSI J J. Strategies for silencing human disease using RNA interference[J]. Nat Rev Genet, 2007, 8: 173-184.
  • 10ANTHONY R V, CANTLON J D. Ribonucleic acid interference:a new approach to the in vivo study of gene function[J]. J Anim Sci, 2007, 85(13 Suppl): E18-E19.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部